Case report: Complete restoration of the HPA axis function in Cushing's disease with drug treatment

Front Endocrinol (Lausanne). 2024 Feb 8:15:1337741. doi: 10.3389/fendo.2024.1337741. eCollection 2024.

Abstract

This report describes a rare case of a 20-year-old man with an ACTH- and prolactin-secreting invasive pituitary macroadenoma causing hyperprolactinemia and Cushing's disease. He was later found to have an AIP mutation. Treatment with cabergoline (1.5 mg weekly) normalized prolactin concentrations and induced a major shrinkage of the adenoma. Not only was urinary free cortisol normalized for more than 14 years, but also the treatment induced normal hypothalamo-pituitary-adrenal (HPA) axis function as illustrated by the reappearance of a normal cortisol/ACTH circadian rhythm, cortisol suppression to dexamethasone, and disappearance of the excessive and aberrant responses to CRH and desmopressin, respectively. This case is the first description of complete restoration of the physiological characteristics of the HPA axis by a medication during the treatment of Cushing's disease. Although exceptional, it illustrates that drugs targeting the pituitary adenoma can bring true complete remission of Cushing's disease.

Keywords: AIP mutation; Cushing’s disease; cabergoline; pituitary macroadenoma; prolactinoma; remission.

Publication types

  • Case Reports

MeSH terms

  • Adrenocorticotropic Hormone
  • Adult
  • Humans
  • Hydrocortisone
  • Hypothalamo-Hypophyseal System
  • Male
  • Pituitary ACTH Hypersecretion* / complications
  • Pituitary ACTH Hypersecretion* / drug therapy
  • Pituitary Neoplasms* / complications
  • Pituitary Neoplasms* / drug therapy
  • Pituitary-Adrenal System
  • Prolactin
  • Young Adult

Substances

  • Hydrocortisone
  • Prolactin
  • Adrenocorticotropic Hormone

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.